New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
09:06 EDTABBV, SGENSeattle Genetics further expands ADC collaboration with AbbVie
Seattle Genetics (SGEN) announced that it has further expanded its antibody-drug conjugate collaboration with AbbVie (ABBV). Under the expanded deal, AbbVie will pay an upfront fee of $25M for additional rights to utilize Seattle Genetics’ ADC technology with AbbVie antibodies against oncology targets, including access to Seattle Genetics’ pyrrolobenzodiazepine dimer ADC technology and EC-mAb site-specific conjugation technology. In addition, Seattle Genetics could receive up to approximately $255M in potential license fees and milestone payments per target, upon achieving predetermined development and commercial objectives, as well as mid-to-high single-digit royalties on worldwide net sales of any resulting products.
News For SGEN;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
16:50 EDTABBVAbbVie extends exchange offer to acquire Pharmacyclics
Subscribe for More Information
April 15, 2015
19:08 EDTABBVEnanta confirms AbbVie hepatitis C treatment granted priority review in Japan
Subscribe for More Information
19:03 EDTABBVAbbVie's chronic hepatitis C treatment granted priority review in Japan
Subscribe for More Information
April 13, 2015
14:07 EDTABBVEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
10:00 EDTABBVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:34 EDTABBVAbbVie upgraded on Imbruvica outlook at BMO Capital
Subscribe for More Information
07:02 EDTABBVAbbVie upgraded to Outperform from Market Perform at BMO Capital
April 10, 2015
07:21 EDTSGENExpert upbeat on Seattle Genetics Adcetris, says RBC Capital
After meeting with an expert, RBC Capital reports that he believes that off-label use of Seattle Genetics' Adcetris is increasing across a variety of indications. He believes that Adcetris is approvable and has a better chance of becoming a front-line treatment than competing drugs. The firm keeps a $50 price target and Outperform rating on the shares.
April 8, 2015
05:30 EDTABBVEnanta announces data on regimens containing protease inhibitors paritaprevir
Subscribe for More Information
April 7, 2015
07:31 EDTABBVBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use